Industry Insight
“This is where the magic happens in pharma and biotech.”


Industry Insight
“This is where the magic happens in pharma and biotech.”
Mats Karlsson, Director Supply Chain, Pfizer
Stockholm insights
The biotech scene in Stockholm–Uppsala is booming, especially when it comes to biomanufacturing. The region is establishing itself as a leading international hub for companies seeking to set up and expand their biomanufacturing facilities.
The biotech scene in Stockholm–Uppsala is booming, especially when it comes to biomanufacturing. The region is establishing itself as a leading international hub for companies seeking to set up and expand their biomanufacturing facilities.
Driven by advances in biomanufacturing technologies, strong R&D investment, regulatory approvals for novel biologics, and growing biosimilar adoption, the global biopharmaceutical market is projected to reach USD 741 billion by 2030, according to market research company Grand View Research.
Sweden is at the forefront of this growth, consistently ranking high in international pharmaceutical approvals and among the top European countries for drug development pipelines. It benefits from an excellent health record system and state-of-the-art testing facilities and is widely trusted for conducting clinical trials. With over 450 registered biobanks and around 100 disease-specific national registries covering 20%–25% of the population, Sweden offers extensive, longitudinal data that supports robust real-world studies.
“This is where the magic happens in pharma and biotech.”
“This is where the magic happens in pharma and biotech.”
Mats Karlsson, Director Supply Chain, Pfizer
A key strength of the Swedish biotech industry is the ongoing collaboration between companies, research facilities, and academic institutions. Swedish firms are highly globally connected, with international experts serving in key advisory and leadership roles. ATMP development (advanced therapy medicinal products), a vital segment of the biotech industry, is a government priority – an area where Sweden excels both in research and production.
There are several reasons for Stockholm–Uppsala’s success in biotech. A diverse and skilled talent pool is a critical factor, alongside stable, productive operating conditions and access to exceptional physical infrastructure – including a strong network of roads, ports, and power grid systems. The strategic importance of biomanufacturing to Sweden means the sector receives ongoing government investment and support. Private investment also plays a major role, with pharmaceutical giants like AstraZeneca and Pfizer investing millions of dollars to expand production facilities in the region in recent years.
As the global importance of biotech and biomanufacturing continues to grow, Stockholm–Uppsala is well poised to become a global leader. The foundation is laid – and ready for the next level.